IRIX - IRIDEX Corp Stock Price, Fair Value and News

2.95USD-0.01 (-0.34%)Market Closed

Market Summary

USD2.95-0.01

Market Closed

-0.34%

IRIX Stock Price

View Fullscreen

IRIX RSI Chart

IRIX Valuation

Market Cap

47.9M

Price/Earnings (Trailing)

-5.01

Price/Sales (Trailing)

0.92

EV/EBITDA

-4.88

Price/Free Cashflow

-7

IRIX Price/Sales (Trailing)

IRIX Profitability

Operating Margin

42.04%

EBT Margin

-18.28%

Return on Equity

-100.5%

Return on Assets

-27.79%

Free Cashflow Yield

-14.3%

IRIX Fundamentals

IRIX Revenue

Revenue (TTM)

51.9M

Rev. Growth (Yr)

-18.01%

Rev. Growth (Qtr)

-3.05%

IRIX Earnings

Earnings (TTM)

-9.6M

Earnings Growth (Yr)

-157.84%

Earnings Growth (Qtr)

-68.76%

Breaking Down IRIX Revenue

Last 7 days

2.8%

Last 90 days

4.2%

Trailing 12 Months

29.4%

How does IRIX drawdown profile look like?

IRIX Financial Health

Current Ratio

2.12

Debt/Equity

0.03

Debt/Cashflow

-21.62

IRIX Investor Care

Shares Dilution (1Y)

1.53%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	57.3M	56.4M	54.6M	51.9M
2022	55.3M	55.7M	57.0M	57.0M
2021	39.3M	46.5M	51.0M	53.9M
2020	41.9M	37.7M	35.8M	36.3M
2019	43.7M	43.8M	43.2M	43.4M
2018	40.6M	40.9M	41.4M	42.6M
2017	44.7M	42.8M	43.9M	41.6M
2016	42.9M	45.8M	45.7M	46.2M
2015	43.3M	41.7M	41.4M	41.8M
2014	39.7M	41.0M	41.6M	42.8M
2013	34.5M	35.3M	36.9M	38.3M
2012	33.3M	33.6M	33.3M	33.9M
2011	29.7M	27.9M	25.4M	33.2M
2010	0	31.5M	31.9M	32.3M
2009	0	0	0	31.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of IRIDEX Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 14, 2023	shuda scott	acquired	75,000	1.91	39,267	-
Jun 14, 2023	ludlum ken	acquired	75,000	1.91	39,267	-
Jun 14, 2023	huss beverly a	acquired	75,000	1.91	39,267	-
Jun 14, 2023	devi nandini	acquired	75,000	1.91	39,267	-
Jun 14, 2023	grove robert earle	acquired	75,000	1.91	39,267	-
Oct 30, 2022	mercer patrick	sold (taxes)	-161	2.27	-71.00	coo
Oct 27, 2022	mercer patrick	acquired	-	-	35,570	coo
Oct 27, 2022	bruce david	acquired	-	-	59,730	president and ceo
Sep 30, 2022	mercer patrick	sold (taxes)	-173	2.41	-72.00	coo
Aug 30, 2022	mercer patrick	sold (taxes)	-181	2.55	-71.00	coo

Which funds bought or sold IRIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	added	89.09	10,000	20,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-9.09	-3,498	93,989	-%
Apr 23, 2024	Venturi Wealth Management, LLC	unchanged	-	127	2,235	-%
Apr 19, 2024	Apexium Financial, LP	unchanged	-	11,168	195,771	0.01%
Apr 15, 2024	WEST PACES ADVISORS INC.	unchanged	-	23.00	402	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	150,444	1,565,730	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	7,002	19,506	19,757	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-32.46	-1,000	-	-%
Feb 14, 2024	PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE	unchanged	-	270,000	2,810,000	6.44%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	20,817	216,651	-%

Are Funds Buying or Selling IRIX?

Are funds buying IRIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IRIX

No. of Funds

Unveiling IRIDEX Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 23, 2022	paragon associates & paragon associates ii joint venture	6.02%	963,250	SC 13D
Sep 20, 2022	roland brent alexander	5.52%	881,998	SC 13D
Sep 01, 2021	paragon associates & paragon associates ii joint venture	4.99%	789,818	SC 13D/A
Jul 02, 2021	paragon associates & paragon associates ii joint venture	6.3%	980,674	SC 13D/A
Jun 21, 2021	blueline capital partners, l.p.	3.2%	493,673	SC 13D/A
Apr 13, 2021	paragon associates & paragon associates ii joint venture	7.3%	1,138,378	SC 13D/A
Mar 23, 2021	topcon america corp	10.4%	1,618,122	SC 13D
Feb 16, 2021	north tide capital, llc	5.5%	760,069	SC 13G/A
Feb 10, 2021	vanguard group inc	5.39%	749,045	SC 13G/A
Feb 04, 2021	global undervalued securities master fund lp	0.0%	0	SC 13G/A

Recent SEC filings of IRIDEX Corp

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report

Peers (Alternatives to IRIDEX Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

IRIDEX Corp News

Latest updates

IRIDEX Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-3.1%	12,458,000	12,850,000	12,855,000	13,706,000	15,195,000	14,635,000	13,755,000	13,387,000	15,254,000	13,264,000	13,426,000	11,959,000	12,304,000	8,803,000	6,219,000	9,021,000	11,762,000	10,664,000	10,426,000	10,595,000	11,467,000
Cost Of Revenue	4.8%	7,573,000	7,229,000	7,492,000	7,768,000	8,531,000	8,175,000	7,488,000	7,410,000	9,252,000	7,482,000	7,318,000	7,020,000	6,722,000	5,149,000	3,813,000	5,105,000	6,912,000	6,381,000	5,877,000	6,338,000	6,762,000
Gross Profit	-13.1%	4,885,000	5,621,000	5,363,000	5,938,000	6,664,000	6,460,000	6,267,000	5,977,000	6,002,000	5,782,000	6,108,000	4,939,000	5,582,000	3,654,000	2,406,000	3,916,000	4,850,000	4,283,000	4,549,000	4,257,000	4,705,000
Operating Expenses	9.0%	7,966,000	7,309,000	8,257,000	8,282,000	8,074,000	8,155,000	8,427,000	8,254,000	8,399,000	7,939,000	7,246,000	6,780,000	5,882,000	5,500,000	5,190,000	5,569,000	6,467,000	6,136,000	7,017,000	7,293,000	7,614,000
S&GA Expenses	1.2%	3,867,000	3,823,000	4,264,000	4,283,000	4,826,000	4,445,000	4,607,000	4,300,000	4,095,000	3,914,000	3,646,000	2,982,000	3,435,000	2,959,000	2,693,000	3,152,000	3,791,000	3,508,000	3,462,000	4,091,000	4,420,000
R&D Expenses	9.9%	1,694,000	1,541,000	1,845,000	1,749,000	1,450,000	1,687,000	1,922,000	2,116,000	2,243,000	1,788,000	1,672,000	1,165,000	887,000	869,000	807,000	719,000	788,000	1,007,000	929,000	958,000	852,000
EBITDA Margin	-23.4%	-0.16	-0.13	-0.13	-0.12	-0.12	-0.14	-0.15	-0.09	-0.08	-0.04	-0.04	-0.16	-	-	-	-	-	-	-	-	-
Income Taxes	650.0%	60,000	8,000	10,000	12,000	14,000	14,000	17,000	20,000	16,000	8,000	8,000	8,000	6,000	8,000	5,000	7,000	26,000	7,000	9,000	6,000	23,000
Earnings Before Taxes	-66.1%	-2,900,000	-1,746,000	-2,756,000	-2,078,000	-1,134,000	-1,753,000	-2,224,000	-2,371,000	-2,427,000	-2,157,000	1,401,000	-2,002,000	-173,000	-1,711,000	-2,775,000	-1,644,000	-1,535,000	-1,778,000	-2,410,000	-3,042,000	-2,833,000
EBT Margin	-29.4%	-0.18	-0.14	-0.14	-0.13	-0.13	-0.15	-0.16	-0.10	-0.10	-0.06	-0.05	-0.17	-	-	-	-	-	-	-	-	-
Net Income	-68.8%	-2,960,000	-1,754,000	-2,766,000	-2,090,000	-1,148,000	-1,767,000	-2,241,000	-2,391,000	-2,443,000	-2,165,000	1,393,000	-2,010,000	-179,000	-1,719,000	-2,780,000	-1,651,000	-1,561,000	-1,785,000	-2,419,000	-3,048,000	-2,856,000
Net Income Margin	-29.9%	-0.18	-0.14	-0.14	-0.13	-0.13	-0.16	-0.17	-0.10	-0.10	-0.06	-0.05	-0.17	-	-	-	-	-	-	-	-	-
Free Cashflow	49.2%	-947,000	-1,864,000	-1,157,000	-2,886,000	-1,673,000	-2,163,000	-2,690,000	-3,279,000	-1,775,000	-695,000	-1,283,000	11,757,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.5%	34.00	35.00	37.00	41.00	42.00	45.00	46.00	48.00	49.00	51.00	51.00	50.00	28.00	28.00	29.00	31.00	35.00	36.00	38.00	41.00	42.00
Current Assets	0.4%	27.00	27.00	31.00	35.00	36.00	38.00	39.00	42.00	42.00	44.00	44.00	44.00	25.00	26.00	26.00	27.00	31.00	31.00	33.00	35.00	40.00
Cash Equivalents	-11.9%	7.00	8.00	10.00	11.00	14.00	16.00	18.00	21.00	24.00	26.00	26.00	28.00	12.00	12.00	12.00	11.00	13.00	13.00	16.00	17.00	21.00
Inventory	-2.1%	10.00	10.00	11.00	11.00	11.00	11.00	10.00	9.00	8.00	9.00	8.00	7.00	6.00	7.00	8.00	8.00	8.00	9.00	9.00	9.00	9.00
Net PPE	-33.0%	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	-3.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	8.9%	25.00	23.00	23.00	25.00	25.00	27.00	26.00	27.00	25.00	25.00	24.00	24.00	11.00	11.00	10.00	10.00	12.00	12.00	13.00	13.00	12.00
Current Liabilities	25.4%	13.00	10.00	12.00	13.00	12.00	14.00	12.00	13.00	13.00	13.00	11.00	13.00	9.00	9.00	8.00	8.00	10.00	9.00	10.00	10.00	11.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	0.00	1.00	1.00	1.00	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	2.00	1.00	2.00	1.00	-	-	-	-	-	-
Shareholder's Equity	-21.1%	10.00	12.00	13.00	16.00	17.00	18.00	19.00	21.00	23.00	25.00	27.00	26.00	17.00	17.00	19.00	21.00	23.00	24.00	26.00	27.00	30.00
Retained Earnings	-3.9%	-79.04	-76.08	-74.33	-71.56	-69.72	-68.57	-66.80	-64.56	-62.17	-59.73	-57.56	-58.95	-56.94	-56.76	-55.05	-52.27	-50.61	-49.05	-47.27	-44.85	-41.80
Additional Paid-In Capital	0.5%	88.00	88.00	88.00	87.00	87.00	86.00	86.00	86.00	85.00	85.00	84.00	84.00	74.00	74.00	74.00	73.00	73.00	73.00	73.00	72.00	72.00
Shares Outstanding	0.1%	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	15.00	15.00	14.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	28.00	-	-	-	32.00	-	-	-	85.00	-	-	-	17.00	-	-	-	34.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	45.1%	-979	-1,782	-1,141	-2,843	-1,590	-2,106	-2,570	-3,253	-1,738	-644	-1,231	11,830	-208	410	-1,986	-1,453	-189	-2,563	-1,364	-3,797	-2,051
Share Based Compensation	9.4%	406	371	400	473	516	377	344	384	365	617	280	366	345	243	436	95.00	305	158	625	615	287
Cashflow From Investing	139.0%	32.00	-82.00	-16.00	-43.00	-83.00	-57.00	-120	-26.00	-37.00	-51.00	-52.00	-5,416	-9.00	-5.00	-11.00	-68.00	-66.00	-133	-147	-163	-134
Cashflow From Financing	287.5%	45.00	-24.00	-63.00	37.00	-	-26.00	-53.00	6.00	39.00	-30.00	-432	9,889	-1.00	-25.00	2,495	-2.00	-5.00	-50.00	-8.00	-93.00	-179

IRIX Income Statement

2023-12-30

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 30, 2023	Dec. 31, 2022
Income Statement [Abstract]
Total revenues	$ 51,869	$ 56,972
Cost of revenues	30,062	31,604
Gross profit	21,807	25,368
Operating expenses:
Research and development	6,829	7,175
Sales and marketing	16,237	18,178
General and administrative	8,748	7,557
Total operating expenses	31,814	32,910
Loss from operations	(10,007)	(7,542)
Other income, net	527	60
Loss from operations before provision for income taxes	(9,480)	(7,482)
Provision for income taxes	90	65
Net loss	$ (9,570)	$ (7,547)
Net loss per share:
Basic	$ (0.59)	$ (0.47)
Diluted	$ (0.59)	$ (0.47)
Weighted average shares used in computing net loss per common share:
Basic	16,128	15,938
Diluted	16,128	15,938

IRIX Balance Sheet

2023-12-30

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 7,034	$ 13,922
Accounts receivable, net	6,727	6,229
Receivable from related party	2,927	3,539
Inventories	9,906	10,608
Prepaid expenses and other current assets	856	1,468
Total current assets	27,450	35,766
Property and equipment, net	351	462
Intangible assets, net	1,642	1,977
Goodwill	965	965
Operating lease right-of-use assets, net	2,632	1,665
Other long-term assets	1,396	1,455
Total assets	34,436	42,290
Current liabilities:
Accounts payable	4,499	3,858
Payable to related party	228	15
Accrued compensation	1,619	2,448
Accrued expenses	1,996	1,548
Other current liabilities	925	968
Accrued warranty	308	168
Deferred revenue	2,404	2,411
Operating lease liabilities	995	1,037
Total current liabilities	12,974	12,453
Long-term liabilities:
Accrued warranty	138	106
Deferred revenue	10,025	11,742
Operating lease liabilities	1,751	732
Other long-term liabilities	26	26
Total liabilities	24,914	25,059
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.01 par value: Authorized: 30,000,000 shares; Issued and outstanding 16,252,813 and 15,989,662 shares as of December 30, 2023 and December 31, 2022, respectively	172	169
Additional paid-in capital	88,444	86,802
Accumulated other comprehensive loss	(52)	(24)
Accumulated deficit	(79,042)	(69,716)
Total stockholders’ equity	9,522	17,231
Total liabilities and stockholders’ equity	$ 34,436	$ 42,290

About IRIDEX Corp

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

CEO	Mr. David I. Bruce
WEBSITE	iridex.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	130

IRIDEX Corp Frequently Asked Questions

What is the ticker symbol for IRIDEX Corp? What does IRIX stand for in stocks?

IRIX is the stock ticker symbol of IRIDEX Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IRIDEX Corp (IRIX)?

As of Fri Apr 26 2024, market cap of IRIDEX Corp is 47.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IRIX stock?

You can check IRIX's fair value in chart for subscribers.

What is the fair value of IRIX stock?

You can check IRIX's fair value in chart for subscribers. The fair value of IRIDEX Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of IRIDEX Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IRIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is IRIDEX Corp a good stock to buy?

The fair value guage provides a quick view whether IRIX is over valued or under valued. Whether IRIDEX Corp is cheap or expensive depends on the assumptions which impact IRIDEX Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IRIX.

What is IRIDEX Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, IRIX's PE ratio (Price to Earnings) is -5.01 and Price to Sales (PS) ratio is 0.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on IRIDEX Corp's stock?

In the past 10 years, IRIDEX Corp has provided -0.096 (multiply by 100 for percentage) rate of return.